Filing Details
- Accession Number:
- 0001209191-14-012247
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-02-20 15:01:43
- Reporting Period:
- 2014-02-18
- Filing Date:
- 2014-02-20
- Accepted Time:
- 2014-02-20 15:01:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1419600 | Flexion Therapeutics Inc | FLXN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1456585 | Versant Side Fund Iii, L.p. | 3000 Sand Hill Road, Bldg 4 Suite 210 Menlo Park CA 94025 | No | No | Yes | No | |
| 1456586 | Versant Venture Capital Iii, L.p. | 3000 Sand Hill Road, Bldg 4, Suite 210 Menlo Park CA 94025 | No | No | Yes | No | |
| 1597416 | Versant Development Fund Iii, L.p. | 3000 Sand Hill Road, Bldg 4, Suite 210 Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-02-18 | 2,036,697 | $0.00 | 2,110,064 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2014-02-18 | 12,029 | $0.00 | 2,122,526 | No | 4 | C | Indirect | By Versant Side Fund III, L.P. |
| Common Stock | Acquisiton | 2014-02-18 | 356,703 | $0.00 | 2,511,209 | No | 4 | C | Indirect | By Versant Development Fund III, LLC |
| Common Stock | Acquisiton | 2014-02-18 | 385,629 | $0.00 | 2,896,838 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2014-02-18 | 2,277 | $0.00 | 2,899,115 | No | 4 | C | Indirect | By Versant Side Fund III, L.P. |
| Common Stock | Acquisiton | 2014-02-18 | 305,886 | $13.00 | 3,205,001 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2014-02-18 | 1,806 | $13.00 | 3,206,807 | No | 4 | P | Indirect | By Versant Side Fund III, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Indirect | By Versant Side Fund III, L.P. |
| No | 4 | C | Indirect | By Versant Development Fund III, LLC |
| No | 4 | C | Direct | |
| No | 4 | C | Indirect | By Versant Side Fund III, L.P. |
| No | 4 | P | Direct | |
| No | 4 | P | Indirect | By Versant Side Fund III, L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2014-02-18 | 16,558,351 | $0.00 | 2,036,697 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2014-02-18 | 97,797 | $0.00 | 12,029 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2014-02-18 | 2,900,000 | $0.00 | 356,703 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2014-02-18 | 3,135,165 | $0.00 | 385,629 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2014-02-18 | 18,512 | $0.00 | 2,277 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The shares are held by Versant Venture Capital III, L.P. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, and Barbara N. Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. Versant Venture Capital III, L.P. is the majority member of Versant Development Fund III, LLC. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, and Barbara N. Lubash disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.
- Every 8.13 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares are held by Versant Side Fund III, L.P. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, and Barbara N. Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. Versant Venture Capital III, L.P. is the majority member of Versant Development Fund III, LLC. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, and Barbara N. Lubash disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.
- The shares are held by Versant Development Fund III, LLC. Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, and Barbara N. Lubash, as managing directors of Versant Ventures III, LLC, share voting and investment authority over the shares held by Versant Venture Capital III, L.P. and Versant Side Fund III, L.P. Versant Venture Capital III, L.P. is the majority member of Versant Development Fund III, LLC. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Samuel D. Colella, Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, and Barbara N. Lubash disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein.
- Every 8.13 shares of Series B Preferred Stock automatically converted into 1 share of Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares were purchased at the Issuer's initial public offering.
Billionaire Hedge Funds
